Drug intelligence / Profile preview

IHC-001

Development stage: Preclinical
Lead developer: Imvax
Modality: Vaccines & Immunotherapeutics
Administration: Implant

Overview

**IHC-001** is an Imvax personalized, autologous whole-tumor-derived cancer immunotherapy being developed for hepatocellular carcinoma. It is an autologous biologic-device combination product that uses patient-derived tumor material and Imvax's implantable biodiffusion-chamber platform to promote immunogenic tumor-cell death, release tumor-associated antigens, and stimulate a systemic antitumor immune response. Imvax lists IHC-001 as an IND-enabling program for hepatocellular carcinoma; preclinical liver-cancer model data showed reduced tumor growth, improved survival, and evidence of durable systemic immunity. ([imvax.com](https://www.imvax.com/pipeline/))

Targets

IGF-1R (Insulin-like growth factor 1 receptor)

Beyond the preview

Go deeper on IHC-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IHC-001.

Explore the full profile